The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound.

A compound of Formula:

##STR00001## or its pharmaceutically acceptable salt, wherein, R.sup.1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula:

##STR00002## wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; -L.sup.1- is O(CR.sup.6R.sup.7)m- or the like; -L.sup.2- is O(CR.sup.6R.sup.7)n- or the like; each R.sup.6 is independently hydrogen or the like; each R.sup.7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R.sup.2 is substituted or unsubstituted alkyl; R.sup.3 is hydrogen or substituted or unsubstituted alkyl; R.sup.4 is substituted or unsubstituted alkylcarbonyl or the like.

The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound.

A compound of Formula:

##STR00001## or its pharmaceutically acceptable salt, wherein, R.sup.1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula:

##STR00002## wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; -L.sup.1- is O(CR.sup.6R.sup.7)m- or the like; -L.sup.2- is O(CR.sup.6R.sup.7)n- or the like; each R.sup.6 is independently hydrogen or the like; each R.sup.7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R.sup.2 is substituted or unsubstituted alkyl; R.sup.3 is hydrogen or substituted or unsubstituted alkyl; R.sup.4 is substituted or unsubstituted alkylcarbonyl or the like.

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis.

##STR00001##

The present disclosure relates to photoactivable protecting groups containing a diarylsulfide chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array synthesis.

##STR00001##

The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanidinium ligand (C) and peroxotungstate anion (D). It further relates to the use of the said catalysts in the manufacture of enantiomerically enriched sulfoxides.

##STR00001##

Corrosion-inhibiting microgels that are suitable for use in non-chromated primer compositions. Each discrete microgel is composed of a cross-linked polymer network and organic corrosion-inhibiting compounds entrapped or immobilized within the polymer network.

Corrosion-inhibiting microgels that are suitable for use in non-chromated primer compositions. Each discrete microgel is composed of a cross-linked polymer network and organic corrosion-inhibiting compounds entrapped or immobilized within the polymer network.

The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: ##STR00001## or its pharmaceutically acceptable salt, wherein, R.sup.1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: ##STR00002## wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; L.sup.1 is O(CR.sup.6R.sup.7)m or the like; L.sup.2 is O(CR.sup.6R.sup.7)n or the like; each R.sup.6 is independently hydrogen or the like; each R.sup.7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R.sup.2 is substituted or unsubstituted alkyl; R.sup.3 is hydrogen or substituted or unsubstituted alkyl; R.sup.4 is substituted or unsubstituted alkylcarbonyl or the like.

The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: ##STR00001## or its pharmaceutically acceptable salt, wherein, R.sup.1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: ##STR00002## wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; L.sup.1 is O(CR.sup.6R.sup.7)m or the like; L.sup.2 is O(CR.sup.6R.sup.7)n or the like; each R.sup.6 is independently hydrogen or the like; each R.sup.7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R.sup.2 is substituted or unsubstituted alkyl; R.sup.3 is hydrogen or substituted or unsubstituted alkyl; R.sup.4 is substituted or unsubstituted alkylcarbonyl or the like.